Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Merck to acquire eye disease firm

by Rowan Walrath
June 1, 2024 | A version of this story appeared in Volume 102, Issue 17

 

Merck & Co. has agreed to buy the ophthalmology firm EyeBio for $1.3 billion up front and up to $1.7 billion in milestone payments. Once the deal closes, Merck will inherit a trispecific antibody called Restoret, which EyeBio is developing as a treatment for vision loss caused by diabetic macular edema and neovascular age-related macular degeneration. Restoret is in early-stage human trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.